Glenmark Pharmaceuticals Latest Updates

Landmark Licensing Deal with AbbVie: Glenmark's subsidiary, Ichnos Glenmark Innovation (IGI), secured a significant global licensing agreement with AbbVie for its experimental cancer drug, ISB 2001. This deal involves an upfront payment of $700 million to IGI, with potential for up to $1.225 billion in additional milestone payments, plus tiered royalties on sales. AbbVie gains exclusive rights to develop and commercialize ISB 2001 in major markets like North America, Europe, Japan, and China, while Glenmark retains rights for Emerging Markets. ISB 2001 is a trispecific T-cell engager in Phase 1 trials for multiple myeloma, with US FDA orphan drug and fast-track designations. Strong Stock Performance: Following the AbbVie deal announcement, Glenmark Pharmaceuticals' shares surged significantly, hitting a lifetime high. Analysts have a positive outlook, with many recommending a 'buy on dips' strategy and setting higher price targets, citing the deal as a transformative event for the company, elevating its position in biologics and innovation-led pharma. Mutual fund holdings in Glenmark Pharma have also seen a notable increase. Financial and Product Developments: Glenmark Pharmaceuticals reported its Q1 FY25 results with a consolidated profit after tax of Rs 340.27 crore and total income of Rs 3,244.19 crore. In late June 2025, Glenmark launched its lung cancer treatment drug, Tevimbra (tislelizumab), in India after receiving approval. The company also received final US FDA approval for Topiramate Capsules USP (generic to Topamax®) in July 2024 and Acetaminophen and Ibuprofen Tablets (OTC) in April 2024.